NO20006023L - Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne - Google Patents

Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne

Info

Publication number: NO20006023L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; cell adhesion; well; compositions containing; adhesion inhibitor
Prior art date: 1998-05-28

Application number

NO20006023A

Other languages

English (en)

Other versions

NO317990B1 (no

NO20006023D0 (no

Inventor

Wen-Cherng Lee

Alan Gill

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-28

Filing date

2000-11-28

Publication date

2001-01-17

2000-11-28 Application filed by Biogen Inc filed Critical Biogen Inc

2000-11-28 Publication of NO20006023D0 publication Critical patent/NO20006023D0/no

2001-01-17 Publication of NO20006023L publication Critical patent/NO20006023L/no

2005-01-17 Publication of NO317990B1 publication Critical patent/NO317990B1/no

Links

230000021164 cell adhesion Effects 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
-1 2-methylphenylamino Chemical group 0.000 abstract 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
229940000635 beta-alanine Drugs 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20006023A 1998-05-28 2000-11-28 Celleadhesjonsinhibitor samt farmasoytiske sammensetninger inneholdende denne NO317990B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8706498P	1998-05-28	1998-05-28
PCT/US1999/011924 WO1999061421A1 (en)	1998-05-28	1999-05-28	A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (3)

Publication Number	Publication Date
NO20006023D0 NO20006023D0 (no)	2000-11-28
NO20006023L true NO20006023L (no)	2001-01-17
NO317990B1 NO317990B1 (no)	2005-01-17

Family

ID=22202907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006023A NO317990B1 (no)	1998-05-28	2000-11-28	Celleadhesjonsinhibitor samt farmasoytiske sammensetninger inneholdende denne

Country Status (30)

Country	Link
US (1)	US6495525B1 (no)
EP (1)	EP1082302B1 (no)
JP (1)	JP2002516309A (no)
KR (1)	KR100636713B1 (no)
CN (1)	CN1148350C (no)
AT (1)	ATE256659T1 (no)
AU (1)	AU764108B2 (no)
BG (1)	BG65021B1 (no)
CA (1)	CA2333656C (no)
CZ (1)	CZ298413B6 (no)
DE (1)	DE69913687T2 (no)
DK (1)	DK1082302T3 (no)
EA (1)	EA002988B1 (no)
EE (1)	EE04639B1 (no)
ES (1)	ES2211096T3 (no)
HU (1)	HUP0102255A3 (no)
IL (1)	IL139967A (no)
IS (1)	IS5737A (no)
MX (1)	MXPA00011774A (no)
NO (1)	NO317990B1 (no)
NZ (1)	NZ509199A (no)
PL (1)	PL198189B1 (no)
PT (1)	PT1082302E (no)
SI (1)	SI1082302T1 (no)
SK (1)	SK285280B6 (no)
TR (1)	TR200100190T2 (no)
UA (1)	UA65623C2 (no)
WO (1)	WO1999061421A1 (no)
YU (1)	YU75500A (no)
ZA (1)	ZA200007300B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2221227T3 (es) *	1997-11-24	2004-12-16	MERCK & CO., INC.	Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
US6645939B1 (en)	1997-11-24	2003-11-11	Merck & Co., Inc.	Substituted β-alanine derivatives as cell adhesion inhibitors
ES2319831T3 (es)	1998-09-14	2009-05-12	Board Of Regents, The University Of Texas System	Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
US7618630B2 (en)	1998-09-14	2009-11-17	Board Of Regents, The University Of Texas System	Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6525069B1 (en)	1998-12-18	2003-02-25	Bristol-Myers Squibb Pharma Co.	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2270868T3 (es)	1999-08-13	2007-04-16	Biogen Idec Ma Inc.	Inhibidores de la adhesion celular.
YU41202A (sh)	1999-12-28	2005-03-15	Pfizer Products Inc.	Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
CA2430978C (en)	2000-12-28	2012-05-15	Daiichi Pharmaceutical Co., Ltd.	Vla-4 inhibitors
JP4676884B2 (ja)	2003-07-24	2011-04-27	第一三共株式会社	シクロヘキサンカルボン酸類
US7419666B1 (en)	2004-02-23	2008-09-02	Massachusetts Eye And Ear Infirmary	Treatment of ocular disorders
US7196112B2 (en)	2004-07-16	2007-03-27	Biogen Idec Ma Inc.	Cell adhesion inhibitors
GT200500321A (es) *	2004-11-09	2006-09-04		Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) *	2006-03-08	2010-03-23	Microsoft Corporation	Multi-cache cooperation for response output caching
JP2009545620A (ja) *	2006-08-02	2009-12-24	ジェンザイム・コーポレーション	併用療法
AU2008219007A1 (en)	2007-02-20	2008-08-28	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja)	2008-04-11	2014-12-10	メリマックファーマシューティカルズインコーポレーティッド	ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh)	2008-11-18	2011-12-14	梅里麦克制药股份有限公司	人血清白蛋白接头以及其结合物
ES2912934T3 (es)	2010-04-16	2022-05-30	Biogen Ma Inc	Anticuerpos anti VLA-4
US9345766B2 (en)	2012-08-30	2016-05-24	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-ERBB3 agents
CN112867394B9 (zh)	2018-06-04	2024-12-06	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体
WO2020092394A1 (en)	2018-10-30	2020-05-07	Gilead Sciences, Inc.	Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da)	2018-10-30	2025-02-17	Gilead Sciences Inc	3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es)	2018-10-30	2024-11-18	Gilead Sciences Inc	Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092401A1 (en)	2018-10-30	2020-05-07	Gilead Sciences, Inc.	COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en)	2019-08-14	2024-02-29	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1149971B (it)	1979-06-11	1986-12-10	Syntex Inc	Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en)	1985-01-23	1988-02-16	Abbott Laboratories	Functionalized peptidylaminoalcohols
US4826815A (en)	1985-05-17	1989-05-02	Abbott Laboratories	Renin inhibiting compounds
DK163689A (da)	1988-04-08	1989-10-30	Sandoz Ag	Peptidderivater
DE69024230T2 (de)	1989-12-22	1996-05-02	Commw Scient Ind Res Org	An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en)	1990-06-07	2003-04-01	Kiyofumi Ishikawa	Endothelin antagonistic peptide derivatives
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
US5260277A (en) *	1990-09-10	1993-11-09	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en)	1990-11-15	1992-05-29	Tanabe Seiyaku Co. Ltd.	Substituted urea and related cell adhesion modulation compounds
DE69226820T2 (de)	1991-06-21	1999-05-12	Merck & Co., Inc., Rahway, N.J.	Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
JPH07503944A (ja)	1991-11-22	1995-04-27	イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド	Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
AU3420693A (en)	1991-12-24	1993-07-28	Fred Hutchinson Cancer Research Center	Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de)	1992-04-13	1993-10-14	Cassella Ag	Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en)	1992-07-26	1996-05-14	Yeda Res & Dev	Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0677060A1 (en)	1993-01-08	1995-10-18	Tanabe Seiyaku Co., Ltd.	Peptide inhibitors of cell adhesion
US5314902A (en)	1993-01-27	1994-05-24	Monsanto Company	Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de)	1993-03-26	1994-09-29	Cassella Ag	Neue Harnstoffderivate, ihre Herstellung und Verwendung
US5922755A (en)	1993-04-09	1999-07-13	Toyama Chemical Co., Ltd.	Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5770573A (en)	1993-12-06	1998-06-23	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en)	1994-03-07	1995-07-18	Warner-Lambert Company	1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
JP2000516596A (ja) *	1996-07-25	2000-12-12	バイオジェン，インコーポレイテッド	細胞接着インヒビター

1999
- 1999-05-28 DK DK99926019T patent/DK1082302T3/da active
- 1999-05-28 NZ NZ509199A patent/NZ509199A/en unknown
- 1999-05-28 YU YU75500A patent/YU75500A/sh unknown
- 1999-05-28 CZ CZ20004425A patent/CZ298413B6/cs not_active IP Right Cessation
- 1999-05-28 PL PL344440A patent/PL198189B1/pl not_active IP Right Cessation
- 1999-05-28 ES ES99926019T patent/ES2211096T3/es not_active Expired - Lifetime
- 1999-05-28 TR TR2001/00190T patent/TR200100190T2/xx unknown
- 1999-05-28 EP EP99926019A patent/EP1082302B1/en not_active Expired - Lifetime
- 1999-05-28 UA UA2000127603A patent/UA65623C2/uk unknown
- 1999-05-28 SI SI9930526T patent/SI1082302T1/xx unknown
- 1999-05-28 EE EEP200000698A patent/EE04639B1/xx not_active IP Right Cessation
- 1999-05-28 CN CNB998080020A patent/CN1148350C/zh not_active Expired - Fee Related
- 1999-05-28 IL IL13996799A patent/IL139967A/xx not_active IP Right Cessation
- 1999-05-28 MX MXPA00011774A patent/MXPA00011774A/es not_active IP Right Cessation
- 1999-05-28 DE DE69913687T patent/DE69913687T2/de not_active Expired - Fee Related
- 1999-05-28 AT AT99926019T patent/ATE256659T1/de not_active IP Right Cessation
- 1999-05-28 HU HU0102255A patent/HUP0102255A3/hu unknown
- 1999-05-28 EA EA200001236A patent/EA002988B1/ru not_active IP Right Cessation
- 1999-05-28 WO PCT/US1999/011924 patent/WO1999061421A1/en not_active Ceased
- 1999-05-28 SK SK1810-2000A patent/SK285280B6/sk not_active IP Right Cessation
- 1999-05-28 KR KR1020007013421A patent/KR100636713B1/ko not_active Expired - Fee Related
- 1999-05-28 PT PT99926019T patent/PT1082302E/pt unknown
- 1999-05-28 JP JP2000550827A patent/JP2002516309A/ja active Pending
- 1999-05-28 AU AU42192/99A patent/AU764108B2/en not_active Ceased
- 1999-05-28 CA CA002333656A patent/CA2333656C/en not_active Expired - Fee Related
2000
- 2000-11-28 US US09/724,107 patent/US6495525B1/en not_active Expired - Fee Related
- 2000-11-28 IS IS5737A patent/IS5737A/is unknown
- 2000-11-28 NO NO20006023A patent/NO317990B1/no unknown
- 2000-12-08 ZA ZA200007300A patent/ZA200007300B/en unknown
- 2000-12-18 BG BG105060A patent/BG65021B1/bg unknown

Also Published As

Publication number	Publication date
NO317990B1 (no)	2005-01-17
SK18102000A3 (sk)	2001-07-10
CA2333656A1 (en)	1999-12-02
PL344440A1 (en)	2001-11-05
CZ298413B6 (cs)	2007-09-26
HK1035726A1 (en)	2001-12-07
EE200000698A (et)	2002-06-17
HUP0102255A2 (hu)	2001-11-28
PL198189B1 (pl)	2008-06-30
EE04639B1 (et)	2006-06-15
BG105060A (en)	2001-08-31
YU75500A (sh)	2002-12-10
EA002988B1 (ru)	2002-12-26
EP1082302B1 (en)	2003-12-17
AU764108B2 (en)	2003-08-07
KR100636713B1 (ko)	2006-10-20
NO20006023D0 (no)	2000-11-28
ES2211096T3 (es)	2004-07-01
CN1148350C (zh)	2004-05-05
ZA200007300B (en)	2002-02-27
JP2002516309A (ja)	2002-06-04
BG65021B1 (bg)	2006-12-29
IL139967A (en)	2005-11-20
TR200100190T2 (tr)	2001-05-21
IS5737A (is)	2000-11-28
CN1307561A (zh)	2001-08-08
DE69913687D1 (de)	2004-01-29
ATE256659T1 (de)	2004-01-15
HUP0102255A3 (en)	2001-12-28
DE69913687T2 (de)	2004-10-07
MXPA00011774A (es)	2002-10-17
EA200001236A1 (ru)	2001-06-25
SK285280B6 (sk)	2006-10-05
WO1999061421A1 (en)	1999-12-02
UA65623C2 (en)	2004-04-15
KR20010043906A (ko)	2001-05-25
CZ20004425A3 (en)	2001-05-16
CA2333656C (en)	2008-07-29
EP1082302A1 (en)	2001-03-14
PT1082302E (pt)	2004-04-30
AU4219299A (en)	1999-12-13
NZ509199A (en)	2003-10-31
SI1082302T1 (en)	2004-06-30
US6495525B1 (en)	2002-12-17
IL139967A0 (en)	2002-02-10
DK1082302T3 (da)	2004-04-26

Publication	Publication Date	Title
NO20006023D0 (no)	2000-11-28	Celleadhesjonsinhibitor samt farmasöytiske sammensetninger inneholdende denne
BG104780A (en)	2001-10-31	Inhibitors of phospholipase enzymes
DK0966465T3 (da)	2003-10-20	Inhibitorer af IMPDH-enzymer
HUP0201214A3 (en)	2002-11-28	Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
EE200000522A (et)	2002-02-15	Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
NL300179I1 (nl)	2005-05-02	Geneesmiddelvoorlopers van trombineremmers.
AU2905495A (en)	1996-01-15	3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
WO2003024899A3 (en)	2003-11-27	CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
MA26492A1 (fr)	2004-12-20	Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
FI942625A7 (fi)	1994-12-05	Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
AU2002218311A1 (en)	2002-06-11	Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
WO2001090138A3 (en)	2002-03-21	SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
ATE252885T1 (de)	2003-11-15	Plan zur verabreichung von h+, k+-atpase inhibitoren
WO2004093788A3 (en)	2005-06-30	Desmoglein 4 is a novel gene involved in hair growth
ATE282607T1 (de)	2004-12-15	Tryptase-inhibitoren
HUP0101899A3 (en)	2001-12-28	Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use
PT830130E (pt)	2004-11-30	Enzima de conversao de tnf-alfa
MA27169A1 (fr)	2005-01-03	Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique
DE60322064D1 (de)	2008-08-21	4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
WO2002057246A3 (en)	2002-11-21	Inhibitors of cruzipain and other cysteine proteases
CO5070670A1 (es)	2001-08-28	Taloproteinasas de arilsulfonamidas y estatinas
ZA200104508B (en)	2002-09-02	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors.
IT1298442B1 (it)	2000-01-10	Composizioni orali a basso dosaggio di proteine citotossiche
ATE281522T1 (de)	2004-11-15	Sentrin-spezifische menschliche protease senp1
FR2654430B1 (fr)	1995-01-06	Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.